Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
复制标题
DOI：
10.3341/kjo.2012.26.3.157
复制
发表时间：
2012-06
影响因子：
--
通讯作者：
Kim JW
中科院分区：
文献类型：
--
作者：
Cho HJ;Baek JS;Lee DW;Kim CG;Kim JW
目的比较贝伐单抗和雷尼比单抗玻璃体腔内注射治疗未治疗的息肉样脉络膜血管病(PCV)的疗效。对连续106例接受贝伐单抗(n=58，1.25 mg)或雷尼比单抗(n=52，0.5 mg)治疗PCV的患者进行了回顾分析。在最初的三次每月负荷注射后，根据需要进行注射。主要观察指标包括最佳矫正视力(BCVA)、光谱域光学相干断层扫描(OCT)评估的中心凹厚度(FCT)以及吲哚青绿血管造影检查息肉样病变的变化。贝伐单抗组平均注射次数为3.31±1.25次，雷尼比单抗组为3.44±0.92次。从基线到注射后6个月，BCVA的最小分辨角度的平均对数在贝伐单抗组和雷尼比单抗组分别提高了0.17(p=0.03)和0.19(p=0.01)。贝伐单抗组平均FCT从322±62.48µm降至274±40.77µm(p=0.02)，雷尼比单抗组从338±50.79µm降至286±36.93µm(p=0.02)。贝伐单抗组息肉消退率为20.7%(12/58眼)，雷尼比珠单抗组为21.2%(11/52眼)。两组间BCVA改善、FCT改善及息肉消退率差异无统计学意义。玻璃体内注射贝伐单抗和雷尼比单抗在短期内对PCV眼的视力稳定、黄斑水肿和息肉复合体消退有相似的效果。
To compare the effectiveness of intravitreal injections of bevacizumab and ranibizumab in patients with treatment-naive polypoidal choroidal vasculopathy (PCV). Records from 106 consecutive patients who received intraviteral bevacizumab (n = 58, 1.25 mg) or ranibizumab (n = 52, 0.5 mg) for treatment of PCV were retrospectively reviewed. After three initial monthly loading injections, injection was performed as needed. The main outcome measures included best-corrected visual acuity (BCVA), foveal central thickness (FCT) as assessed by spectral domain optical coherence tomography, and the changes in polypoidal lesions based on an indocyanine green angiography. The average number of injections was 3.31 ± 1.25 in the bevacizumab group and 3.44 ± 0.92 in the ranibizumab group. Mean logarithm of the minimum angle of resolution of BCVA from baseline to 6 months after injection improved by 0.17 in the bevacizumab group (p = 0.03) and by 0.19 in the ranibizumab group (p = 0.01). Average FCT decreased from 322 ± 62.48 µm to 274 ± 40.77 µm in the bevacizumab group (p = 0.02) and from 338 ± 50.79 µm to 286 ± 36.93 µm in the ranibizumab group (p = 0.02). Polyp regression rate was 20.7% (12 of 58 eyes) in the bevacizumab group and 21.2% (11 of 52 eyes) in the ranibizumab group. There was no statistically significant difference between groups in BCVA improvement achieved, FCT improvement achieved, and polyp regression rate between groups. Intravitreal injections of bevacizumab and ranibizumab have similar effects in stabilizing of visual acuity, macular edema, and regression of polypoidal complex in PCV eyes over the short term.